Elizabeth Cormier-May

Elizabeth Cormier-May has a strong background in the field of healthcare and diagnostics. Elizabeth currently holds the position of President & CEO and Chairman of the Board of Directors at Dragonfly Data Ventures, where they focus on empowering individuals to take ownership of their personal data. Additionally, they are the CEO of Mammogen, Inc., where they aim to improve early detection and enhance treatment for diseases. Elizabeth also serves as a Partner & Chief Commercial Officer at IV BioHoldings, a company dedicated to advancing precision health on a global scale.

Elizabeth's experience also includes serving as a Board Director at Safe & Green Holdings Corp., an Advisory Board Member at 2San, and a Healthcare Innovation and Diagnostics Advisor at Boat School Ventures. Elizabeth is an Advisory Board Member at PragmaDx, Inc. as well. In their prior roles, Elizabeth served as the Vice President and Head of Commercial Diagnostics at Exosome Diagnostics, the Director of Business Development, Diagnostics at Definiens, The Tissue Phenomics Company, and the Director of Companion Diagnostics Sales-Pharmaceuticals at HTG Molecular Diagnostics.

Throughout their career, Elizabeth has consistently demonstrated a commitment to advancing healthcare and improving disease detection, diagnosis, and treatment.

Elizabeth Cormier-May attended Wheaton College Massachusetts from 2000 to 2004, where they earned a Bachelor of Science degree with ACS Certification in Organic Chemistry. Additionally, they studied Chemistry and Chemical Biology at Northeastern University, although no specific degree or years of study were provided.